Annual CFF
$11.82 M
+$7.33 M+163.10%
December 31, 2023
Summary
- As of February 8, 2025, RGLS annual cash flow from financing activities is $11.82 million, with the most recent change of +$7.33 million (+163.10%) on December 31, 2023.
- During the last 3 years, RGLS annual CFF has risen by +$2.30 million (+24.21%).
- RGLS annual CFF is now -86.61% below its all-time high of $88.24 million, reached on December 31, 2014.
Performance
RGLS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$56.00 K
+$800.00 K+107.53%
September 30, 2024
Summary
- As of February 8, 2025, RGLS quarterly cash flow from financing activities is $56.00 thousand, with the most recent change of +$800.00 thousand (+107.53%) on September 30, 2024.
- Over the past year, RGLS quarterly CFF has increased by +$800.00 thousand (+107.53%).
- RGLS quarterly CFF is now -99.94% below its all-time high of $93.11 million, reached on March 31, 2024.
Performance
RGLS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$91.54 M
-$231.00 K-0.25%
September 30, 2024
Summary
- As of February 8, 2025, RGLS TTM cash flow from financing activities is $91.54 million, with the most recent change of -$231.00 thousand (-0.25%) on September 30, 2024.
- Over the past year, RGLS TTM CFF has dropped by -$231.00 thousand (-0.25%).
- RGLS TTM CFF is now -19.34% below its all-time high of $113.49 million, reached on September 30, 2013.
Performance
RGLS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RGLS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +163.1% | +107.5% | -0.3% |
| 3 y3 years | +24.2% | +100.0% | +182.5% |
| 5 y5 years | +517.5% | +187.5% | +475.2% |
RGLS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -78.0% | +163.1% | -99.9% | +106.4% | -13.4% | +2384.9% |
| 5 y | 5-year | -78.0% | +163.1% | -99.9% | +105.2% | -13.4% | +2384.9% |
| alltime | all time | -86.6% | +517.5% | -99.9% | +102.2% | -19.3% | +3285.3% |
Regulus Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $56.00 K(-107.5%) | $91.54 M(-0.3%) |
| Jun 2024 | - | -$744.00 K(-100.8%) | $91.78 M(-13.2%) |
| Mar 2024 | - | $93.11 M(<-9900.0%) | $105.73 M(+794.8%) |
| Dec 2023 | $11.82 M(+163.1%) | -$873.00 K(-404.2%) | $11.82 M(-6.9%) |
| Sep 2023 | - | $287.00 K(-97.8%) | $12.69 M(-24.9%) |
| Jun 2023 | - | $13.21 M(-1740.6%) | $16.89 M(+358.5%) |
| Mar 2023 | - | -$805.00 K(<-9900.0%) | $3.68 M(-18.0%) |
| Dec 2022 | $4.49 M(-91.6%) | $0.00(-100.0%) | $4.49 M(-87.8%) |
| Sep 2022 | - | $4.49 M(>+9900.0%) | $36.90 M(+13.9%) |
| Jun 2022 | - | $0.00(-100.0%) | $32.41 M(-31.6%) |
| Mar 2022 | - | $2000.00(-100.0%) | $47.40 M(-11.8%) |
| Dec 2021 | $53.74 M(+464.9%) | $32.41 M(<-9900.0%) | $53.74 M(+71.2%) |
| Sep 2021 | - | -$4000.00(-100.0%) | $31.39 M(+3.5%) |
| Jun 2021 | - | $15.00 M(+136.7%) | $30.32 M(+90.5%) |
| Mar 2021 | - | $6.34 M(-37.0%) | $15.92 M(+67.3%) |
| Dec 2020 | $9.51 M(-76.2%) | $10.05 M(-1041.5%) | $9.51 M(-60.3%) |
| Sep 2020 | - | -$1.07 M(-280.1%) | $23.97 M(-4.0%) |
| Jun 2020 | - | $593.00 K(-985.1%) | $24.97 M(-36.3%) |
| Mar 2020 | - | -$67.00 K(-100.3%) | $39.21 M(-1.8%) |
| Dec 2019 | $39.93 M(-1511.1%) | $24.51 M(<-9900.0%) | $39.93 M(+210.8%) |
| Sep 2019 | - | -$64.00 K(-100.4%) | $12.85 M(+6.8%) |
| Jun 2019 | - | $14.83 M(+2157.1%) | $12.03 M(-518.6%) |
| Mar 2019 | - | $657.00 K(-125.5%) | -$2.87 M(+1.6%) |
| Dec 2018 | -$2.83 M | -$2.57 M(+191.0%) | -$2.83 M(+996.9%) |
| Sep 2018 | - | -$884.00 K(+1078.7%) | -$258.00 K(-100.6%) |
| Jun 2018 | - | -$75.00 K(-110.7%) | $43.77 M(-0.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $701.00 K(>+9900.0%) | $43.85 M(+1.0%) |
| Dec 2017 | $43.41 M(+111.2%) | $0.00(-100.0%) | $43.41 M(+0.1%) |
| Sep 2017 | - | $43.15 M(>+9900.0%) | $43.37 M(+9411.6%) |
| Jun 2017 | - | $0.00(-100.0%) | $456.00 K(-97.8%) |
| Mar 2017 | - | $268.00 K(-738.1%) | $20.29 M(-1.3%) |
| Dec 2016 | $20.55 M(+192.9%) | -$42.00 K(-118.3%) | $20.55 M(-7.6%) |
| Sep 2016 | - | $230.00 K(-98.8%) | $22.23 M(-13.0%) |
| Jun 2016 | - | $19.84 M(+3656.8%) | $25.54 M(+285.3%) |
| Mar 2016 | - | $528.00 K(-67.8%) | $6.63 M(-5.5%) |
| Dec 2015 | $7.02 M(-92.0%) | $1.64 M(-53.7%) | $7.02 M(-91.6%) |
| Sep 2015 | - | $3.54 M(+284.1%) | $83.24 M(+4.2%) |
| Jun 2015 | - | $922.00 K(+0.8%) | $79.86 M(+1.1%) |
| Mar 2015 | - | $915.00 K(-98.8%) | $78.97 M(-10.5%) |
| Dec 2014 | $88.24 M(+89.9%) | $77.87 M(>+9900.0%) | $88.24 M(+751.1%) |
| Sep 2014 | - | $157.00 K(+375.8%) | $10.37 M(-81.6%) |
| Jun 2014 | - | $33.00 K(-99.7%) | $56.45 M(-0.0%) |
| Mar 2014 | - | $10.18 M(<-9900.0%) | $56.48 M(+21.5%) |
| Dec 2013 | $46.47 M(-34.1%) | -$4000.00(-100.0%) | $46.47 M(-59.1%) |
| Sep 2013 | - | $46.24 M(>+9900.0%) | $113.49 M(+59.8%) |
| Jun 2013 | - | $60.00 K(-65.3%) | $71.01 M(+0.4%) |
| Mar 2013 | - | $173.00 K(-99.7%) | $70.73 M(+0.4%) |
| Dec 2012 | $70.48 M(<-9900.0%) | $67.01 M(+1681.8%) | $70.48 M(+1931.8%) |
| Sep 2012 | - | $3.76 M(-1825.2%) | $3.47 M(-1288.0%) |
| Jun 2012 | - | -$218.00 K(+194.6%) | -$292.00 K(+294.6%) |
| Mar 2012 | - | -$74.00 K | -$74.00 K |
| Dec 2011 | -$354.00 K(-102.4%) | - | - |
| Dec 2010 | $14.69 M | - | - |
FAQ
- What is Regulus Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Regulus Therapeutics?
- What is Regulus Therapeutics annual CFF year-on-year change?
- What is Regulus Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Regulus Therapeutics?
- What is Regulus Therapeutics quarterly CFF year-on-year change?
- What is Regulus Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Regulus Therapeutics?
- What is Regulus Therapeutics TTM CFF year-on-year change?
What is Regulus Therapeutics annual cash flow from financing activities?
The current annual CFF of RGLS is $11.82 M
What is the all time high annual CFF for Regulus Therapeutics?
Regulus Therapeutics all-time high annual cash flow from financing activities is $88.24 M
What is Regulus Therapeutics annual CFF year-on-year change?
Over the past year, RGLS annual cash flow from financing activities has changed by +$7.33 M (+163.10%)
What is Regulus Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of RGLS is $56.00 K
What is the all time high quarterly CFF for Regulus Therapeutics?
Regulus Therapeutics all-time high quarterly cash flow from financing activities is $93.11 M
What is Regulus Therapeutics quarterly CFF year-on-year change?
Over the past year, RGLS quarterly cash flow from financing activities has changed by +$800.00 K (+107.53%)
What is Regulus Therapeutics TTM cash flow from financing activities?
The current TTM CFF of RGLS is $91.54 M
What is the all time high TTM CFF for Regulus Therapeutics?
Regulus Therapeutics all-time high TTM cash flow from financing activities is $113.49 M
What is Regulus Therapeutics TTM CFF year-on-year change?
Over the past year, RGLS TTM cash flow from financing activities has changed by -$231.00 K (-0.25%)